Elite Pharmaceuticals, Inc. (ELTP) Operating income 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) annual operating income history from SEC filings — each fiscal year as reported.
$49.1MFY2026 · since FY2017: -$7.4M → $49.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $49.1M | +150.6% |
| FY2025 | $19.6M | +81.7% |
| FY2024 | $10.8M | +193.5% |
| FY2023 | $3.7M | -27.5% |
| FY2022 | $5.1M | +140.9% |
| FY2021 | $2.1M | +192.1% |
| FY2020 | -$2.3M | +75.0% |
| FY2019 | -$9.2M | -1.2% |
| FY2018 | -$9.1M | -23.0% |
| FY2017 | -$7.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Gross marginELTP Operating marginELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →